FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735652803> ?p ?o ?g. }

• W2735652803 endingPage "153" @default.
• W2735652803 startingPage "147" @default.
• W2735652803 abstract "123I-meta-iodobenzylguanidine (123I-MIBG) imaging is currently a mainstay in the evaluation of many neuroendocrine tumors, especially neuroblastoma. 123I-MIBG imaging has several limitations that can be overcome by the use of a PET agent. 18F-meta-fluorobenzylguanidine (18F-MFBG) is a PET analog of MIBG that may allow for single-day, high-resolution quantitative imaging. We conducted a first-in-human study of 18F-MFBG PET imaging to evaluate the safety, feasibility, pharmacokinetics, and dosimetry of 18F-MFBG in neuroendocrine tumors (NETs). Methods: Ten patients (5 with neuroblastoma and 5 with paraganglioma/pheochromocytoma) received 148-444 MBq (4-12mCi) of 18F-MFBG intravenously followed by serial whole-body imaging at 0.5-1, 1-2, and 3-4 after injection. Serial blood samples (a total of 6) were also obtained starting at 5 min after injection to as late as 4 h after injection; whole-body distribution and blood clearance data, lesion uptake, and normal-tissue uptake were determined, and radiation-absorbed doses to normal organs were calculated using OLINDA. Results: No side effects were seen in any patient after 18F-MFBG injection. Tracer distribution showed prominent activity in the blood pool, liver, and salivary glands that decreased with time. Mild uptake was seen in the kidneys and spleen, which also decreased with time. Urinary excretion was prominent, with an average of 45% of the administered activity in the bladder by 1 h after injection; whole-body clearance was monoexponential, with a mean biologic half-life of 1.95 h, whereas blood clearance was biexponential, with a mean biologic half-life of 0.3 h (58%) for the rapid α phase and 6.1 h (42%) for the slower β phase. The urinary bladder received the highest radiation dose with a mean absorbed dose of 0.186 ± 0.195 mGy/MBq. The mean total-body dose was 0.011 ± 0.011 mGy/MBq, and the effective dose was 0.023 ± 0.012 mSv/MBq. Both skeletal and soft-tissue lesions were visualized with high contrast. The SUVmax (mean ± SD ) of lesions at 1-2 h after injection was 8.6 ± 9.6. Conclusion: Preliminary data show that 18F-MFBG imaging is safe and has favorable biodistribution and kinetics with good targeting of lesions. PET imaging with 18F-MFBG allows for same-day imaging of NETs. 18F-MFBG appears highly promising for imaging of patients with NETs, especially children with neuroblastoma." @default.
• W2735652803 created "2017-07-21" @default.
• W2735652803 creator A5010076893 @default.
• W2735652803 creator A5012407611 @default.
• W2735652803 creator A5015396908 @default.
• W2735652803 creator A5024109107 @default.
• W2735652803 creator A5029385885 @default.
• W2735652803 creator A5031628518 @default.
• W2735652803 creator A5032598163 @default.
• W2735652803 creator A5042102358 @default.
• W2735652803 creator A5050680844 @default.
• W2735652803 creator A5056859109 @default.
• W2735652803 creator A5063044283 @default.
• W2735652803 creator A5068928963 @default.
• W2735652803 creator A5080877411 @default.
• W2735652803 date "2017-07-13" @default.
• W2735652803 modified "2023-10-15" @default.
• W2735652803 title "Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies" @default.
• W2735652803 cites W189310225 @default.
• W2735652803 cites W1946923111 @default.
• W2735652803 cites W1991796941 @default.
• W2735652803 cites W2003352409 @default.
• W2735652803 cites W2019059397 @default.
• W2735652803 cites W2037211078 @default.
• W2735652803 cites W2046291757 @default.
• W2735652803 cites W2057339874 @default.
• W2735652803 cites W2081252169 @default.
• W2735652803 cites W2102640940 @default.
• W2735652803 cites W2110103490 @default.
• W2735652803 cites W2118018889 @default.
• W2735652803 cites W2118660125 @default.
• W2735652803 cites W2121537624 @default.
• W2735652803 cites W2147575945 @default.
• W2735652803 cites W2155254558 @default.
• W2735652803 cites W2155333681 @default.
• W2735652803 cites W2157770758 @default.
• W2735652803 cites W2158310959 @default.
• W2735652803 cites W2226076446 @default.
• W2735652803 cites W2320822566 @default.
• W2735652803 cites W63097450 @default.
• W2735652803 cites W80051168 @default.
• W2735652803 doi "https://doi.org/10.2967/jnumed.117.193169" @default.
• W2735652803 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5750519" @default.
• W2735652803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28705916" @default.
• W2735652803 hasPublicationYear "2017" @default.
• W2735652803 type Work @default.
• W2735652803 sameAs 2735652803 @default.
• W2735652803 citedByCount "88" @default.
• W2735652803 countsByYear W27356528032017 @default.
• W2735652803 countsByYear W27356528032018 @default.
• W2735652803 countsByYear W27356528032019 @default.
• W2735652803 countsByYear W27356528032020 @default.
• W2735652803 countsByYear W27356528032021 @default.
• W2735652803 countsByYear W27356528032022 @default.
• W2735652803 countsByYear W27356528032023 @default.
• W2735652803 crossrefType "journal-article" @default.
• W2735652803 hasAuthorship W2735652803A5010076893 @default.
• W2735652803 hasAuthorship W2735652803A5012407611 @default.
• W2735652803 hasAuthorship W2735652803A5015396908 @default.
• W2735652803 hasAuthorship W2735652803A5024109107 @default.
• W2735652803 hasAuthorship W2735652803A5029385885 @default.
• W2735652803 hasAuthorship W2735652803A5031628518 @default.
• W2735652803 hasAuthorship W2735652803A5032598163 @default.
• W2735652803 hasAuthorship W2735652803A5042102358 @default.
• W2735652803 hasAuthorship W2735652803A5050680844 @default.
• W2735652803 hasAuthorship W2735652803A5056859109 @default.
• W2735652803 hasAuthorship W2735652803A5063044283 @default.
• W2735652803 hasAuthorship W2735652803A5068928963 @default.
• W2735652803 hasAuthorship W2735652803A5080877411 @default.
• W2735652803 hasBestOaLocation W27356528031 @default.
• W2735652803 hasConcept C112705442 @default.
• W2735652803 hasConcept C126322002 @default.
• W2735652803 hasConcept C142724271 @default.
• W2735652803 hasConcept C150903083 @default.
• W2735652803 hasConcept C151337348 @default.
• W2735652803 hasConcept C207001950 @default.
• W2735652803 hasConcept C2775842073 @default.
• W2735652803 hasConcept C2776410896 @default.
• W2735652803 hasConcept C2776715637 @default.
• W2735652803 hasConcept C2776734335 @default.
• W2735652803 hasConcept C2777807558 @default.
• W2735652803 hasConcept C2778172261 @default.
• W2735652803 hasConcept C2779066768 @default.
• W2735652803 hasConcept C2779762690 @default.
• W2735652803 hasConcept C2779902710 @default.
• W2735652803 hasConcept C2780931953 @default.
• W2735652803 hasConcept C2989005 @default.
• W2735652803 hasConcept C54355233 @default.
• W2735652803 hasConcept C71924100 @default.
• W2735652803 hasConcept C75088862 @default.
• W2735652803 hasConcept C81885089 @default.
• W2735652803 hasConcept C86803240 @default.
• W2735652803 hasConceptScore W2735652803C112705442 @default.
• W2735652803 hasConceptScore W2735652803C126322002 @default.
• W2735652803 hasConceptScore W2735652803C142724271 @default.
• W2735652803 hasConceptScore W2735652803C150903083 @default.
• W2735652803 hasConceptScore W2735652803C151337348 @default.
• W2735652803 hasConceptScore W2735652803C207001950 @default.

• next